Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation, Restricted Stock and Stock Options (Tables)

v3.20.1
Stock-Based Compensation, Restricted Stock and Stock Options (Tables)
 9 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]  
Schedule of stock based compensation expenses

    Three months ended
December 31,		     Nine months ended
December 31,		  
    2019     2018     2019     2018  
                         
Research and development expenses   $ 455,820     $ 113,740     $ 1,437,334     $ 346,586  
Selling, general and administrative expenses     896,291       92,631       2,781,142       296,917  
Total stock-based compensation   $ 1,352,111     $ 206,371     $ 4,218,476     $ 643,503  

Schedule of restricted stock awards

    Number of Shares     Weighted Average Grant-Date
Fair Value		  
Unvested at March 31, 2019     -     $ -  
Granted     6,000,000     $ 0.82  
Vested     (1,499,994 )   $ 0.82  
Unvested at December 31, 2019 (Unaudited)     4,500,006     $ 0.82  

Schedule of stock options

    Shares Underlying Options     Weighted Average Exercise Price     Weighted Average Remaining Contractual
Term (Years)		     Aggregate Intrinsic Value  
Outstanding at March 31, 2019     5,813,500     $ 0.18       9.2     $ 3,720,395  
Outstanding at December 31, 2019 (Unaudited)     5,813,500     $ 0.18       8.5     $ 3,313,450  
                                 
Exercisable at December 31, 2019 (Unaudited)     3,008,436     $ 0.19       8.5     $ 1,672,452